Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Top Performing Drug of 2021 - Keytruda (May Edition)
Top Performing Drug of 2021 – Keytruda (May Edition)
Active Ingredients: Pembrolizumab Strength: 100 mg/4 mL (25 mg/mL) Dosage Form: Syringe, Vial Mechanism of Action: PD-1 ligands antagonists First Approval: US (Sep 4, 2014), EU (Jul 17, 2015) Revenue Keytruda (pembrolizumab) has been a key player in Merck & Co. immuno-oncology drugs for the past years – reaching nearly $17B in annual sales in 2021. Despite the dampening impact…
May 26, 2022
Insights+ The US FDA New Drug Approvals in April 2022
Insights+: The US FDA New Drug Approvals in April 2022
The US FDA has approved 6 NDAs in Apr 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 26 novel products in 2022 In Apr 2022, the major highlights drugs were Vivjoa for Recurrent Vulvovaginal Candidiasis, Cuvrior for Stable Wilson’s Disease, Igalmi for Acute Treatment of Agitation…
May 19, 2022
Disease of the Month: Dengue Disease
Disease of the Month: Dengue Diseas
In India, 16 May is observed as National Dengue Day. Dengue is a mosquito-borne viral disease transmitted by female mosquitoes of the Aedes aegypti species infected by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4)2. These mosquitoes belong to the family Flaviviridae. They bite during the day. As per WHO reports,…
May 16, 2022
Insights+ Key Biosimilars Events of April 2022
Insights+ Key Biosimilars Events of April 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Alvotech resolved a European patent dispute with…
May 5, 2022
Top Performing Drug of 2021 - Humira (April Edition)
Top Performing Drug of 2021 – Humira (April Edition)
Active Ingredients: Adalimumab Strength: 40 mg/0.8 ml Dosage Form: Syringe, Vial Mechanism of Action: TNF-alpha inhibitors First Approval: US (Dec 31, 2002), EU (Aug 09, 2003) Revenue Humira (adalimumab) has been the top-selling biologic drug product for the last few years – reaching nearly $21B in annual sales in 2021. Humira is one of the main drivers of AbbVie’s immunology…
April 29, 2022
Top Performing Drugs of 2021: A Monthly Series by PharmaShots
Top Performing Drugs of 2021: A Monthly Series by PharmaShots
The year 2021 witnessed the global approval of vaccines and drugs amid COVID-19. The disease has been dominating the headlines from the last two years. No one is amazed that COVID vaccines and drugs find a place in top selling drugs this time. Pfizer & BioNTech’s Comirnaty took the first position with $36B revenue and…
April 28, 2022
Insights+ The US FDA New Drug Approvals in March 2022
Insights+: The US FDA New Drug Approvals in March 2022
The US FDA has approved 9 NDAs and 1 BLAs in Mar 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 20 novel products in 2022 In Mar 2022, the major highlights drugs were Adlarity for Alzheimer's Disease, Rinvoq for Ulcerative Colitis, Ztalmy for CDKL5 Deficiency Disorder…
April 21, 2022
Disease of the Month: Chagas Disease (American Trypanosomiasis)
Disease of the Month: Chagas Disease (American Trypanosomiasis)
INTRODUCTION Chagas disease also known by the name American trypanosomiasis, is a zoonotic infection, caused by protozoan flagellate Trypanosoma cruzi (kissing bugs). It is potentially a life-threatening infection transmitted to people and animals from the feces of blood-sucking bugs which belong to the subfamily of Triatominae2. Among all the vectors, Rhodnius proxilus, Panstrongylus megistus, and…
April 14, 2022
Insights+ Key Biosimilars Events of March 2022
Insights+ Key Biosimilars Events of March 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of March, Junshi & Mabwell Bioscience’s Junmaikang (biosimilar, adalimumab)…
April 7, 2022
PharmaShots' Key Highlights of First Quarter 2022
PharmaShots’ Key Highlights of First Quarter 2022
The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3B The first quarter of the year also showcases regulatory events…
March 31, 2022
Load more